School of Medicine
Showing 11-20 of 25 Results
Michelle L. James
Assistant Professor of Radiology (Molecular Imaging Program at Stanford) and of Neurology
Current Research and Scholarly Interests The primary aim of my lab is to improve the diagnosis and treatment of brain diseases by developing translational molecular imaging agents for visualizing neuroimmune interactions underlying conditions such as Alzheimer?s disease, multiple sclerosis, and stroke.
Professor of Radiology (Molecular Imaging Program at Stanford/Nuclear Medicine) and, by courtesy, of Physics, of Electrical Engineering and of Bioengineering
Current Research and Scholarly Interests Molecular Imaging Instrumentation
Our research interests involve the development of novel instrumentation and software algorithms for in vivo imaging of cellular and molecular signatures of disease in humans and small laboratory animal subjects.
Professor of Biomedical Data Science and, by courtesy, of Radiology (Molecular Imaging) and of Epidemiology and Population Health
Current Research and Scholarly Interests Biostatistics, clinical trials, statistical evaluation of medical diagnostic tests, radiology, osteoporosis, meta-analysis, medical decisoin making
Chirag Patel, MD, PhD
Clinical Assistant Professor, Neurology & Neurological Sciences
Current Research and Scholarly Interests Neuro-oncology, Clinical Trials, Tumor Treating Fields (TTFields), Molecular/PET Imaging, Neuroimaging, Immunotherapy, Big Data Analysis
Professor of Radiology (Molecular Imaging Program at Stanford) and, by courtesy, of Chemistry
Current Research and Scholarly Interests Probe chemistry and nanotechnology for molecular imaging and diagnostics
Professor of Otolaryngology - Head & Neck Surgery (OHNS) and of Radiology (Molecular Imaging Program at Stanford)
Bio Eben Rosenthal is a surgeon-scientist and academic leader. He is currently serving as the John and Ann Doerr Medical Director of the Stanford Cancer Center, a position he has held since July 2015. He works collaboratively with the Stanford Cancer Institute and Stanford Health Care leaders to set the strategy for the clinical delivery of cancer care across Stanford Medicine and growing cancer networks.
Before coming to Stanford, he learned his surgical skills in otolaryngology from the University of Michigan and traveled west for further training in facial plastic and reconstructive surgery at the Oregon Health and Science University. He joined the faculty at University of Alabama at Birmingham where he started as an Assistant Professor of Surgery within the Division of Otolaryngology. In 2012, Dr. Rosenthal became Division Director of Otolaryngology ? Head and Neck Surgery and the holder of the John S. Odess Endowed Chair at the University of Alabama at Birmingham. He moved to Stanford in 2015 to become the Ann and John Doerr Medical Director of the Stanford Cancer Center.
Dr. Rosenthal is certified by the American Board of Otolaryngology and is a Diplomat of the American Board of Facial Plastic and Reconstructive Surgery. He specializes in the treatment and reconstruction of head and neck cancer patients. He has a strong interest in development of new strategies to surgically repair complex head and neck defects to improve functional and cosmetic outcomes.
He has published over 160 peer-reviewed scientific manuscripts, authored many book chapters and published a book on optical imaging in cancer. He is on the editorial board of Head & Neck and The Laryngoscope and is also a charter member of the NIH Developmental Therapeutics Study Section. Dr. Rosenthal has performed preclinical and clinical research on the role of targeted therapies for use to treat cancer alone and in combination with conventional therapy. He has served as principal investigator on several early phase investigator-initiated and industry sponsored clinical trials in molecular oncology. He has received grant funding from the American Cancer Society, NIH/NCI and NIH/NIDCR to study the role of targeted therapy and novel imaging strategies in cancer.
Dr. Rosenthal has conducted bench to bedside development of optical contrast agents to identify cancer in the operating room. He led a multidisciplinary team of scientists through successful IND application to allow testing of fluorescently labeled antibodies in the clinic and operating room. These early phase clinical trials have demonstrated that this technique can visualize microscopic cancer in the operating room and may significantly improve clinical outcomes.